MMJ backs up intent with cash
Published 01-MAR-2016 16:13 P.M.
|
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Biotech company MMJ PhytoTech (ASX:MMJ) has given the most concrete evidence to date that it’s serious about a market entry into Australia – raising $5 million for the task.
It told its shareholders earlier today that it had issued just a shade over 20.8 million shares at a 20% discount on the 15 day volume weighted average price of the stock to institutional investors keen for a slice of the action.
While the $5 million has been raised for a market entry, some of the cash will be put aside toward a phase two trial of its Pro-Nano-Liposheres oral capsule in Israel.
The company had hailed the phase one trial as a success – especially when compared to market leader Sativex.
The bulk of the money, however, will go towards an Australian market entry – although MMJ has yet to spell out exactly what form this would take.
MMJ first flagged its intention to enter the Australian market back in October last year on the back of state-based legislative moves around the legalisation of medical cannabis.
Legislation passed through the federal senate last week, which among other things moved cannabis into the same restricted drug class as morphine instead of being classed as an illicit drug.
Also on the regulatory front MMJ hailed a recent federal court ruling in Canada which effectively gives the Canadian government six months to introduce a new or parallel federal medical cannabis regime.
The case which brought about the ruling was based on limitations on access to the current regime, including a ban on personal cultivation for patients with a prescription.
Instead of being alarmed at the prospect of individuals growing their own supply, MMJ said the move would invigorate the space – comparing home cultivation to the home brew of beer.
It pointed to its plan to supply genetic and quality testing services, which it said could be extended to individual patients rather than commercial growers.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
